⚕️ Medical note: Decisions about reproductive and longevity medicine should be made in consultation with qualified clinicians. This article is informational.
When researchers at Columbia University published findings in 2024 showing that ovarian aging could be meaningfully slowed in mouse models through targeted molecular interventions, it generated significant attention in the longevity science community. What received less attention, outside specialist circles, was the implication of the associated finding: that ovarian aging doesn’t just affect fertility and oestrogen levels, but appears to act as a pacemaker for systemic aging across multiple organ systems in female biology.
That implication — that the ovary is not merely a reproductive organ but a regulator of broader biological aging in women — reframes the entire conversation about women’s health across the lifespan. It suggests that interventions targeting ovarian aging might have benefits extending well beyond the symptoms of menopause into cardiovascular health, brain health, metabolic function, and longevity itself.
The Pacemaker Hypothesis
The ovaries produce not only oestrogen but also a range of factors — anti-Müllerian hormone, activins, inhibins, and others — that have widespread regulatory effects throughout the body. As ovarian function declines, these signals change not just locally but systemically. Research from Columbia’s VIBRANT (Vocabulary, Intelligence, Brain Activity and Telomere Length) programme has been tracking the relationship between ovarian reserve and cognitive function, finding that women with lower ovarian reserve (as measured by AMH levels) show earlier declines in specific cognitive domains than would be predicted by chronological age alone.
The cardiovascular connection is even better established. Women have substantially lower rates of cardiovascular disease than men before menopause, and this protection is lost relatively rapidly in the years following the menopause transition. The loss tracks closely with the decline in oestrogen production, and large epidemiological studies confirm that early menopause (before 45) significantly increases lifetime cardiovascular risk. This isn’t simply about hormone replacement — it’s about understanding why the ovary’s decline has systemic effects and whether that trajectory can be modified.
What’s Being Investigated
Several interventional approaches are currently in various stages of investigation. NAD+ precursors — specifically NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — have shown evidence of improving mitochondrial function in ovarian tissue in animal models, and early human trials are exploring whether they improve egg quality and ovarian reserve markers. The mitochondrial biology is relevant because oocytes (eggs) have extraordinarily high energy demands and their mitochondrial function is a critical determinant of their developmental competence.
Senolytic drugs — compounds that selectively clear senescent (dysfunctional, pro-inflammatory) cells — are being investigated for their effects on ovarian function. As the ovary ages, it accumulates senescent cells that create a local inflammatory environment hostile to the remaining follicles. Clearing these cells in mouse models has shown promise in slowing follicle depletion, and early phase trials in humans are underway.
Platelet-rich plasma (PRP) injection into ovarian tissue — controversial and currently outside standard clinical practice — has been piloted in several small trials, showing tentative improvements in ovarian reserve markers in perimenopausal women. The evidence is preliminary and the practice is not recommended outside clinical trial settings, but it represents one approach being explored.
The Research Gap That Still Exists
Despite the progress, the research funding disparity in women’s health remains significant. Endometriosis, a condition affecting 10% of women of reproductive age, spent decades severely under-researched relative to its prevalence. Menopause, a transition affecting 100% of women who live long enough, is in a similar position. The clinical tools available to women managing the menopause transition — primarily HRT, which has been available since the 1940s — have barely changed, while the science suggesting more targeted approaches is beginning to mature.
The good news is that this is changing. Dedicated women’s health biotech companies, academic programmes specifically focused on ovarian biology, and increasing patient advocacy are driving research that was not being funded a decade ago. The ovarian aging science is not yet at a stage where clinical recommendations can be substantially updated, but the direction of the research is clear and the rate of progress is accelerating.
Such a great article. I really loved it